scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of proprietary buffered formulation of furosemide, which is delivered through the SmartDose drug delivery system for treatment of congestion in decompensated heart failure patients. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. to incorporate SmartDose drug delivery system with Furoscix. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
IPO Year: 2017
Exchange: NASDAQ
Website: scpharmaceuticals.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/7/2023 | $20.00 | Buy | Craig Hallum |
| 12/1/2022 | $25.00 | Outperform | Cowen |
| 10/21/2022 | $14.00 | Buy | Jefferies |
| 10/11/2022 | $11.00 | Mkt Perform → Outperform | SVB Leerink |
| 8/2/2022 | $10.00 | Buy | Maxim Group |
| 9/9/2021 | $6.00 | Market Perform | SVB Leerink |
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
10-Q - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
DEFA14A - scPharmaceuticals Inc. (0001604950) (Filer)
DEF 14A - scPharmaceuticals Inc. (0001604950) (Filer)
S-8 - scPharmaceuticals Inc. (0001604950) (Filer)
10-K - scPharmaceuticals Inc. (0001604950) (Filer)
8-K - scPharmaceuticals Inc. (0001604950) (Filer)
SCHEDULE 13G/A - scPharmaceuticals Inc. (0001604950) (Subject)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
4 - scPharmaceuticals Inc. (0001604950) (Issuer)
Submission status for SCPHARMACEUTICALS INC's drug FUROSCIX (ORIG-1) with active ingredient FUROSEMIDE has changed to 'Approval' on 10/07/2022. Application Category: NDA, Application Number: 209988, Application Classification: Type 3 - New Dosage Form